Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Cerebrospinal fluid levels of neurofilament and tau correlate with brain atrophy in natalizumab-treated multiple sclerosis.

Mellergård J, Tisell A, Blystad I, Grönqvist A, Blennow K, Olsson B, Dahle C, Vrethem M, Lundberg P, Ernerudh J.

Eur J Neurol. 2017 Jan;24(1):112-121. doi: 10.1111/ene.13162. Epub 2016 Oct 4.

PMID:
27699930
2.

A validated gene regulatory network and GWAS identifies early regulators of T cell-associated diseases.

Gustafsson M, Gawel DR, Alfredsson L, Baranzini S, Björkander J, Blomgran R, Hellberg S, Eklund D, Ernerudh J, Kockum I, Konstantinell A, Lahesmaa R, Lentini A, Liljenström HR, Mattson L, Matussek A, Mellergård J, Mendez M, Olsson T, Pujana MA, Rasool O, Serra-Musach J, Stenmarker M, Tripathi S, Viitala M, Wang H, Zhang H, Nestor CE, Benson M.

Sci Transl Med. 2015 Nov 11;7(313):313ra178. doi: 10.1126/scitranslmed.aad2722.

3.

Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.

Mellergård J, Edström M, Jenmalm MC, Dahle C, Vrethem M, Ernerudh J.

PLoS One. 2013 Dec 2;8(12):e81685. doi: 10.1371/journal.pone.0081685. eCollection 2013.

4.

Association between change in normal appearing white matter metabolites and intrathecal inflammation in natalizumab-treated multiple sclerosis.

Mellergård J, Tisell A, Dahlqvist Leinhard O, Blystad I, Landtblom AM, Blennow K, Olsson B, Dahle C, Ernerudh J, Lundberg P, Vrethem M.

PLoS One. 2012;7(9):e44739. doi: 10.1371/journal.pone.0044739. Epub 2012 Sep 17.

5.

Transcriptional characteristics of CD4+ T cells in multiple sclerosis: relative lack of suppressive populations in blood.

Edström M, Mellergård J, Mjösberg J, Jenmalm M, Vrethem M, Press R, Dahle C, Ernerudh J.

Mult Scler. 2011 Jan;17(1):57-66. doi: 10.1177/1352458510381256. Epub 2010 Sep 16.

PMID:
20847001
6.

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid.

Mellergård J, Edström M, Vrethem M, Ernerudh J, Dahle C.

Mult Scler. 2010 Feb;16(2):208-17. doi: 10.1177/1352458509355068. Epub 2009 Dec 9.

PMID:
20007431
7.

In vitro Th2 deviation of myelin-specific peripheral blood lymphocytes from patients with multiple sclerosis.

Hallin E, Mellergård J, Vrethem M, Ernerudh J, Ekerfelt C.

J Neuroimmunol. 2006 Feb;171(1-2):156-62. Epub 2005 Oct 26.

PMID:
16256209
8.

Short- and long-term effects of T-cell modulating agents in experimental autoimmunity.

Mellergård J, Havarinasab S, Hultman P.

Toxicology. 2004 Mar 15;196(3):197-209.

PMID:
15036746

Supplemental Content

Loading ...
Support Center